



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449 (Rev. 10-01-99)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page 1 of

Complete if Known

Application Number	09/856,927
Filing Date	May 29, 2001
First Named Inventor	DEAN et al.
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	015280-382100US

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
SSH	AA	WO	98/55614	A2	12-10-1998			<input type="checkbox"/>
SSH	AB	WO	99/40110	A1	08-12-1999			<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SSH	AC	Allikmets et al., "Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the Expressed Sequence Tags database", <i>Human Molecular Genetics</i> 5:10: 1649-1655 (1996).	
SSH	AD	Lee et al., "Reduced Drug Accumulation and Multidrug Resistance in Human Breast Cancer Cells Without Associated P-Glycoprotein or MRP Overexpression", <i>Journal of Cellular Biochemistry</i> 65: 513-526 (1997).	
SSH	AE	Doyle et al., "Cloning and characterization of Breast Cancer Resistance Protein (BCRP), a novel ATP-binding cassette (ABC) transporter that may contribute to the multidrug-resistance phenotype of MCF-7/AdrVp breast cancer cells", <i>Proceedings of the American Association for Cancer Research</i> 39: 657 (1998).	
SSH	AF	Lage et al., "Cloning and characterization of human cDNAs encoding a protein with high homology to rat intestinal development protein OCI-5", <i>Gene</i> 188: 151-156 (1997).	
↓	AG	Bruin et al., "Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR", <i>Cancer letters</i> 146: 117-126 (1999).	
↓	AH	Miyake et al., "Molecular Cloning of cDNAs Which are Highly Overexpressed in Mitoxantrone-resistant cells: Demonstration of Homology to ABC Transport Genes", <i>Cancer Research</i> 59: 8-13 (1999).	
SSH	AI	Allikmets et al., "A Human Placenta-specific ATP-Binding Cassette Gene (ABCP) on Chromosome 4q22 That is Involved in Multidrug Resistance", <i>Cancer Research</i> 58: 5337-5339 (1998).	
SSH	AJ	Doyle et al., "A multidrug resistance transporter from human MCF-7 breast cancer cells", <i>Proc. Natl. Acad. Sci. USA</i> 95: 15665-15670 (1998).	

Examiner
Signature

Date
Considered

8/8/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.